Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Benzinga Newsdesk www.benzinga.com Negative 83.3%

Neg 83.3% Neu 0% Pos 0%

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.